ReviewPharmacogenetics and genomics2015
PharmGKB summary: very important pharmacogene information for CYP4F2.
Review in Pharmacogenetics and genomics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Recommendations for Clinical Warfarin Genotyping Allele Selection: A Report of the Association for Molecular Pathology and the College of American Pathologists.The Journal of molecular diagnostics : JMD · 2020Guideline
- CYP3A4, CYP3A5, and CYP4F2 Polymorphisms and Bleeding Risk in Ticagrelor-Based Dual Antiplatelet Therapy.Medicina (Kaunas, Lithuania) · 2026Observational
- Understanding the Genetic Architecture of Vitamin Status Biomarkers in the Genome-Wide Association Study Era: Biological Insights and Clinical Significance.Advances in nutrition (Bethesda, Md.) · 2024Review
- PharmVar GeneFocus: CYP4F2.Clinical pharmacology and therapeutics · 2024Review
- Whole-genome sequencing across 449 samples spanning 47 ethnolinguistic groups provides insights into genetic diversity in Nigeria.Cell genomics · 2023Article
- Computational analysis of missense variant CYP4F2*3 (V433M) in association with human CYP4F2 dysfunction: a functional and structural impact.BMC molecular and cell biology · 2023Article
- Suggestive evidence of CYP4F2 gene polymorphisms with HAPE susceptibility in the Chinese Han population.PloS one · 2023Article
- Personalised Medicine: implication and perspectives in the field of occupational health.La Medicina del lavoro · 2020Article
- Role of CYP4F2 as a novel biomarker regulating malignant phenotypes of liver cancer cells via the Nrf2 signaling axis.Oncology letters · 2020Article
- Brazilian cohort and genes encoding for drug-metabolizing enzymes and drug transporters.Pharmacogenomics · 2020Article
- Role of Genetic Variations in the Hepatic Handling of Drugs.International journal of molecular sciences · 2020 · on this mapReview
- Factors associated with platelet reactivity during dual antiplatelet therapy in patients with diabetes after acute coronary syndrome.Scientific reports · 2020Article
- Interpretation of the effect of CYP2C9, VKORC1 and CYP4F2 variants on warfarin dosing adjustment in Turkey.Molecular biology reports · 2019Article
- Integrated analysis of genetic variation and gene expression reveals novel variant for increased warfarin dose requirement in African Americans.Journal of thrombosis and haemostasis : JTH · 2017Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.